Combining two immunotherapy drugs upfront for advanced melanoma appears to increase the two-year survival rate over that achieved with a single agent, according to an analysis of results from a multi-center phase II clinical trial, scientists report.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe